Company news
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) news
Alaunos Therapeutics, Inc. news releases on 6ix. Latest, Sep 18, 2026: Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced…
Press releases & updates
Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules
September 18, 2026
Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study
June 29, 2026
Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies
May 26, 2026
Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models
May 18, 2026
Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders
March 2, 2026
Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering
June 23, 2025
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)
May 14, 2025
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
November 13, 2023
Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives
August 13, 2023
Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies
June 28, 2023
ALAUNOS THERAPEUTICS, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
June 12, 2023
Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting
May 24, 2023
Alaunos Therapeutics Reports First Quarter 2023 Financial Results
May 9, 2023
Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023
May 2, 2023
Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
April 25, 2023
ALAUNOS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement (form 8-K)
April 3, 2023
Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors
March 29, 2023
Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
March 6, 2023
Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock
November 28, 2022
Alaunos Therapeutics Announces Proposed Public Offering of Common Stock
November 27, 2022
Alaunos Therapeutics Reports Third Quarter 2022 Financial Results
November 13, 2022
Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022
November 7, 2022
Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference
September 20, 2022
Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell Therapy
September 5, 2022
Alaunos Therapeutics Reports Second Quarter 2022 Financial Results
August 14, 2022
Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations
August 3, 2022
Alaunos Therapeutics and the National Cancer Institute Extend Cooperative Research and Development Agreement for Development of Personalized TCR-T Cell Therapies to 2025
June 26, 2022
Alaunos Therapeutics Reports First Quarter 2022 Financial Results
May 15, 2022
Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022
May 8, 2022
Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors
May 1, 2022
Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
March 29, 2022
Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022
March 15, 2022